Phase II
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Combination of Novel Gene Therapy and Immunotherapy Being Evaluated for Synergistic Anti-Tumor Activity in Patients with Cancer with Limited Treatment Options
Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and U.S. centers.
Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001.
BerGenBio ASA presents study updates from its Phase II clinical development programme with bemcentinib, a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer at the 2019 World Conference on Lung Cancer in Barcelona, Spain.
The fifth annual CAR-TCR Summit will kick off in Boston Tuesday with a focus on advancements in immunotherapies targeting various cancers, as well as challenges that face the field.
Neurotrope announced that its Phase II trial of Bryostatin-1 in moderate to severe Alzheimer’s disease did not show statistical significance on the primary endpoint, change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.
When Eli Lilly and Company acquired Loxo Oncology for $8 billion, the company was gambling on several pipeline drugs in oncology.
Ultragenyx Pharmaceutical Inc. announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus based gene therapy for the treatment of glycogen storage disease type Ia.
Apogenix announced that a new publication in Cancer Management and Research[1] reviews asunercept as a promising treatment option for patients with other malignancies beyond glioblastoma and myelodysplastic syndromes.
PRESS RELEASES